论文部分内容阅读
目的探讨尼莫地平联合依达拉奉治疗高血压性脑出血的临床价值,为高血压性脑出血的临床治疗提供参考。方法将医院2012年4月-2014年4月收治的90例高血压性脑出血患者随机分为观察组和对照组各45例,对照组给予内科常规治疗,观察组在对照组的基础上给予尼莫地平联合依达拉奉进行治疗,治疗1个疗程后对2组患者治疗效果进行比较和分析。结果经治疗,观察组水肿及血肿体积显著小于对照组,NIHSS评分显著低于对照组,治疗总有效率为86.67%显著高于对照组的64.44%,差异均具有统计学意义(P<0.05)。结论尼莫地平联合依达拉奉治疗高血压性脑出血效果显著,有利于患者脑组织中血肿的吸收,在极大程度上改善了患者的神经功能,值得临床推广。
Objective To investigate the clinical value of nimodipine and edaravone in the treatment of hypertensive intracerebral hemorrhage and provide reference for the clinical treatment of hypertensive intracerebral hemorrhage. Methods 90 patients with hypertensive intracerebral hemorrhage admitted from April 2012 to April 2014 in our hospital were randomly divided into observation group (45 cases) and control group (45 cases). The control group was given routine medical treatment. The observation group was given on the basis of the control group Nimodipine combined edaravone treatment, treatment of a course of treatment after two groups of patients were compared and analyzed. Results After treatment, the volume of edema and hematoma in the observation group was significantly smaller than that in the control group, and the NIHSS score was significantly lower than that in the control group. The total effective rate was 86.67%, significantly higher than that of the control group (64.44%), with significant difference (P <0.05) . Conclusion Nimodipine combined with edaravone is effective in treating hypertensive intracerebral hemorrhage and is beneficial to the absorption of hematoma in brain tissue of patients. It greatly improves the neurological function of patients and deserves clinical promotion.